Publications


















Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations.
Am J Hematol 2011 Dec 22;86(12):E64-6. Epub 2011 Sep 22.
Department of Medical Sciences, University of Milano and Hematology 1, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.









Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma.
Stem Cells Dev 2007 Dec;16(6):921-30
Institute of Basic Medical Sciences and School of Basic Medicine, Center of Excellence in Tissue Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.


The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Blood 2007 Jul 19;110(1):334-8. Epub 2007 Mar 19.
Hematology and Bone Marrow Transplantation Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy.

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation.
Blood 2005 Oct 2;106(7):2472-83. Epub 2005 Jun 2.
Laboratory of Hematology, Hematology and Bone Marrow Transplantation (BMT) Center, Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy.





Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
Biomed Res Int 2015 22;2015:172458. Epub 2015 Oct 22.
Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, 43126 Parma, Italy ; UO di Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy.




OF